{"product_id":"global-cancer-biologics-market-size-study-forecast-by-product-monoclonal-antibodies-cytokine-based-immunotherapy-cancer-vaccines-car-t-cell-therapy-and-immune-checkpoint-inhibitors-by-application-non-small-cell-lung-cancer-prostate-cancer-bre","title":"Global Cancer Biologics Market Size study \u0026 Forecast, by Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, and Immune Checkpoint Inhibitors), by Application (Non-small Cell Lung Cancer, Prostate Cancer, Bre","description":"\u003cp\u003eGlobal Cancer Biologics Market Size study \u0026amp; Forecast, by Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, and Immune Checkpoint Inhibitors), by Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Others), by Distribution Channel (Hospitals, Clinics, and Others) and Regional Analysis, 2023-2030\u003cbr\u003e\nGlobal Cancer Biologics Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Cancer biologics refer to a class of drugs that are designed to target specific molecules or pathways involved in the growth and spread of cancer cells. They are typically derived from living organisms, such as proteins, antibodies, and vaccines, and are designed to interact with specific targets on cancer cells. These drugs are often used in the treatment of various types of cancer and may be used alone or in combination with other treatments, such as chemotherapy, radiation therapy, or surgery. Cancer biologics may also be referred to as biologic therapies, biotherapeutics, or targeted therapies. The major driving factors for the Global Cancer Biologics Market are increasing incidences of cancer and increasing demand for targeted and personalized medicine. Moreover, technological advancements and favorable regulatory environment are creating lucrative growth opportunities in the market over the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eThe rising incidences of cancer are one of the primary drivers of the cancer biologics market. Globally, the number of new cases of cancer was 19.3 million in 2020, according to the GLOBOCAN 2020 statistics. This number is expected to increase to 30.2 million by 2040. This significant rise in cancer cases underscores the urgent need for effective cancer treatments, including small molecule drugs, which have shown promise in the treatment of various types of cancer. However, the high cost of Cancer Biologics stifles market growth throughout the forecast period of 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Cancer Biologics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East \u0026amp; Africa. The North American market for cancer biologics is expected to be the largest due to the presence of major pharmaceutical companies, high healthcare expenditure, and increasing cancer prevalence. The US is expected to dominate the market due to the high adoption rate of advanced cancer treatments. The Asia-Pacific market for cancer biologics is expected to witness significant growth due to factors such as increasing cancer prevalence, improving healthcare infrastructure, and increasing investment in R\u0026amp;D. China and Japan are expected to be the major contributors to the market growth.\u003c\/p\u003e\n\n\u003cp\u003eMajor market players included in this report are:\u003cbr\u003e\nRoche Holding AG\u003cbr\u003e\nNovartis AG\u003cbr\u003e\nMerck \u0026amp; Co., Inc.\u003cbr\u003e\nBristol-Myers Squibb Company\u003cbr\u003e\nAmgen Inc.\u003cbr\u003e\nJohnson \u0026amp; Johnson\u003cbr\u003e\nPfizer Inc.\u003cbr\u003e\nAstraZeneca plc\u003cbr\u003e\nEli Lilly and Company\u003cbr\u003e\nAbbVie Inc.\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\nIn January 2020, F. Hoffmann-La Roche AG announced that it had submitted a supplemental biological license application to the U.S. Food and Drug Administration (FDA) for Tecentriq (atezolizumab), in combination with the drug Avastin (bevacizumab), for the treatment of the most common form of liver cancer.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Cancer Biologics Market Report Scope:\u003cbr\u003e\nHistorical Data – 2020 - 2021\u003cbr\u003e\nBase Year for Estimation – 2022\u003cbr\u003e\nForecast period - 2023-2030\u003cbr\u003e\nReport Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered - Product, Application, Distribution Channel, Region\u003cbr\u003e\nRegional Scope - North America; Europe; Asia Pacific; Latin America; Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.\u003c\/p\u003e\n\n\u003cp\u003eThe detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Product:\u003cbr\u003e\nMonoclonal Antibodies\u003cbr\u003e\nCytokine-Based Immunotherapy\u003cbr\u003e\nCancer Vaccines\u003cbr\u003e\nCAR-T Cell Therapy\u003cbr\u003e\nImmune Checkpoint Inhibitors\u003c\/p\u003e\n\n\u003cp\u003eBy Application:\u003cbr\u003e\nNon-small Cell Lung Cancer\u003cbr\u003e\nProstate Cancer\u003cbr\u003e\nBreast Cancer\u003cbr\u003e\nAcute Myeloid Leukemia\u003cbr\u003e\nLymphoma\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Distribution Channel:\u003cbr\u003e\nHospitals\u003cbr\u003e\nClinics\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Region:\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003c\/p\u003e\n\n\u003cp\u003eLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003cbr\u003e\nSaudi Arabia\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nRest of Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003cbr\u003e\nRoche Holding AG\u003cbr\u003e\nNovartis AG\u003cbr\u003e\nMerck \u0026amp; Co., Inc.\u003cbr\u003e\nBristol-Myers Squibb Company\u003cbr\u003e\nAmgen Inc.\u003cbr\u003e\nJohnson \u0026amp; Johnson\u003cbr\u003e\nPfizer Inc.\u003cbr\u003e\nAstraZeneca plc\u003cbr\u003e\nEli Lilly and Company\u003cbr\u003e\nAbbVie Inc.\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"July, 2023 \/ 200 Pages \/ MCW16230942","offer_id":47647234588978,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-cancer-biologics-market-size-study-forecast-by-product-monoclonal-antibodies-cytokine-based-immunotherapy-cancer-vaccines-car-t-cell-therapy-and-immune-checkpoint-inhibitors-by-application-non-small-cell-lung-cancer-prostate-cancer-bre","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}